

Key Conclusions

IDEA WS NAMs and Derivation of NESILs

October 10, 2024

Against the overall objective of providing a NAMs based risk assessment in form of an SCCS dossier the WS recommended the following:

1. RCPL – Next steps

The WS participants agreed on an extension and refinement of the RCPL towards a more diverse reference dataset to evaluate NAMs and allowing more confidence in predictions.

2. Assessment of NAMs

The preliminary analysis of the GARD dose response and the regression model versus current RCPL looks promising however some outliers require further follow up.

It was recommended to expand the scope of NAMs comparison with the (extended) RCPL, in the first instance by including SARA ICE.

3. Consideration of uncertainty

Characterization of areas of additional uncertainty that might be associated with the incorporation of NAMs into the risk assessment process need to be a key topic in the next workshop.

4. Dealing with very weak sensitizers

To progress the topic the draft commentary using benzyl alcohol as an example will be shared with the WS participants for comments.